文献速递皮肤肿瘤

皮下脂膜炎样T细胞淋巴瘤:16例病例系列的临床特征、治疗方式与结局

Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients.
PubMed 文献 · J Am Acad Dermatol · 2018-08-17

该回顾性多中心研究分析了1996至2016年间诊断的16例皮下脂膜炎样T细胞淋巴瘤(SPTCL)患者,总结其临床、病理、治疗及结局特征。口服类固醇单用或联合低剂量甲氨蝶呤或环孢素A是最常见初始治疗,在85%接受治疗的患者中达到完全缓解。5年疾病特异性生存率为85.7%,作者认为SPTCL预后极佳,可考虑免疫抑制治疗作为一线方案。

要点

  • SPTCL常表现为累及腿部和/或躯干的多发结节或斑块,25%伴自身免疫病,18%发生噬血细胞综合征。
  • 口服类固醇单用或联合低剂量甲氨蝶呤或环孢素A初始治疗,85%达完全缓解。
  • 5年疾病特异性生存率为85.7%,作者认为免疫抑制治疗可考虑作为一线方案。

核心结论

  • SPTCL预后极佳,可考虑免疫抑制药物作为一线治疗。

研究设计与样本

  • 回顾性多中心研究,纳入1996年至2016年间诊断的16例SPTCL患者。

主要发现

  • 女性与男性比例为1.7,诊断时中位年龄为46.5岁。
  • 患者表现为多发结节或斑块样皮损,优先累及腿部和/或躯干。
  • 组织病理学典型表现为小叶性脂膜炎,单个脂肪细胞被非典型淋巴细胞环绕,通常呈CD3+、CD4-、CD8+、CD56-、TIA1阳性表型且增殖率高。
  • 25%的患者合并自身免疫病,18%的患者发生噬血细胞综合征。
  • 口服类固醇单用或联合低剂量甲氨蝶呤或环孢素A是最常见初始治疗,在接受治疗的患者中85%达到完全缓解,中位随访时间14个月,5年疾病特异性生存率为85.7%。

关键数值与推荐

  • 口服类固醇单用或联合低剂量甲氨蝶呤或环孢素A初始治疗,完全缓解率为85%。
  • 5年疾病特异性生存率为85.7%。

临床怎么用

  • 作者认为免疫抑制药物可考虑作为SPTCL的一线治疗。

局限性

  • 本研究为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare primary cutaneous lymphoma of mature cytotoxic T cells. Initially, patients with SPTCL were treated with doxorubicin-based polychemotherapy. OBJECTIVE: To analyze clinical, biologic, immunophenotypical, molecular, imaging, treatment, and outcome data reflecting the current state of knowledge. METHODS: A retrospective multicenter study of 16 patients with SPTCL that was diagnosed between 1996 and 2016. RESULTS: The female-to-male ratio was 1.7. The median age at diagnosis was 46.5 years. Patients presented with multiple nodular or plaque-like lesions preferentially affecting the legs and/or trunk. Histopathology typically showed a lobular panniculitis with individual adipocytes surrounded by atypical lymphocytes, usually with a CD3+, CD4-, CD8+, CD56-, TIA1 cytotoxic granule associated RNA binding protein 1-positive phenotype and high proliferation rate. SPTCL was associated with autoimmune diseases in 25% of patients, and with the development of hemophagocytic syndrome in 18% of patients. Oral steroids alone or in combination with low-dose methotrexate or cyclosporine A were the most common initial treatment, achieving a complete response in 85% of the treated patients. The median follow-up time was 14 months. The 5-year disease-specific survival rate was 85.7%. LIMITATIONS: This was a retrospective study. CONCLUSIONS: SPTCL has an excellent prognosis. Immunosuppressive agents can be considered for first-line treatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. López-Lerma I, Peñate Y, Gallardo F, et al. Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients. J Am Acad Dermatol. 2018. PMID: 30126736. doi:10.1016/j.jaad.2018.05.1243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。